TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05542043

Intervention type: OTHER
Intervention: Data collection
Description: The data includes anamnestic and clinical data from women whose placental histology reveals a diagnosis of placental dysfunction.~Maternal data on the following characteristics: age, ethnicity, BMI, pregnancy, parity, number of abortions without curettage, multiple births, previous birth mode.~Risk factors for placentation disorders (increased maternal age, increased pregnancy and parity, increased BMI, placenta previa, nicotine abuse, multiple births, hypertension, diabetes, infections, bleeding, abortion curettage, hysteroscopy ± cavum curettage, caesarean section, fibroid removal, Asherman' s syndrome, status after IVF, endometritis) and birth mode.~Data on peripartal and postpartum surgical measures.
Study: NCT00774514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
Study: NCT02405910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study: NCT01718678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: it is kind of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is Placebo
Study: NCT03284814

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose intervention with Standard product (SP)
Description: hard capsules, 100 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Standard product (SP)
Description: hard capsules, 100 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose intervention with Standard product (SP)
Description: hard capsules, 100 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose intervention with Comparative product (CP)
Description: soft-gel capsules, 100 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Comparative product (CP)
Description: soft-gel capsules, 100 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose intervention with Comparative product (CP)
Description: soft-gel capsules, 100 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose intervention with Investigational product (IP)
Description: syrup, 100 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose intervention with Investigational product (IP)
Description: syrup, 100 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple dose intervention with Standard product (SP)
Description: hard capsules, 100 mg - 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple dose intervention with Comparative product (CP)
Description: soft-gel capsules, 100 mg - 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple dose intervention with Investigational product (IP)
Description: syrup, 100 mg - 14 days
Study: NCT03269630

Intervention type: OTHER
Intervention: No intervention. Biospecimen collection only
Description: Biospecimen collection

Intervention type: OTHER
Intervention: No intervention. Biospecimen collection only
Description: Biospecimen collection

Intervention type: OTHER
Intervention: No intervention. Biospecimen collection only
Description: Biospecimen collection
Study: NCT02962453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning walk
Description: gait training with Morning walk three times during 5 minutes with 5 minute break a day over 5 weekdays

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ground Walker
Description: gait training with ground walker until corresponding 200 steps during 5 minutes with 5 minute break a day over 5 weekdays
Study: NCT00322231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zoster vaccine live (ZOSTAVAX™)
Description: 1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zoster vaccine live (ZOSTAVAX™)
Description: 1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: 1 dose 0.65 mL/dose subcutaneous injection of placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: 1 dose 0.65 mL/dose subcutaneous injection of placebo.
Study: NCT02423330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strattice-LIFT
Description: Patients undergoing surgery for transsphincteric anal fistulas will undergo the Strattice-LIFT procedure. A standard LIFT procedure will be performed with the addition of Strattice placed into the intersphincteric space.
Study: NCT02405910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT04854720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuji® II LC CAPSULE
Description: Fuji® II LC is a resin modified glass ionomer contained, fluoride releasing and light-cured material. Since the product is tolerant to moisture and saliva, it's used for fissure sealant of newly erupted teeth.~Test 1 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.The tooth surface was rinsed with water and dried. Thereafter, Fuji® II LC was applied to the pits and fissures on the tooth surface using a brush. Then, the varnish was applied and cured according to the manufacturer's instructions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinpro™ XT Varnish
Description: Clinpro™ XT Varnish is a resin modified glass ionomer containing, fluoride-releasing, light-cured varnish. Since the product is tolerant to moisture and saliva, it is used for fissure sealant of newly erupted teeth. The product can be recharged with fluoride using fluoride-containing products.~Test 2 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 35% phosphoric acid was applied to all surfaces of the tooth for 15 seconds.Then the tooth surface was rinsed with water and dried. Thereafter, Clinpro™ XT Varnish was applied in compliance with the manufacturers' instructions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beautifil Flow
Description: Beautiful Flow is a Giomer contained, fluoride releasing and light cured material. The product contains pre-reacted glass ionomer particles (PRG). It is a high water resistant material. It is used for fissure sealant.~Test 3 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 7% phosphoric acid was applied to all surfaces of the tooth for 10 seconds. Then the tooth surface was rinsed with water and dried. Afterwards, a two-stage self-etch adhesive system was applied. Thereafter, Beautiful Flow was applied in compliance with the manufacturers' instructions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuji Triage® CAPSULE
Description: Fuji Triage® is a new generation glass ionomer containing with low viscosity, high fluoride content and light curing materials. Since the product is tolerant of moisture and saliva, it is used for fissure sealant of newly erupted teeth.~Control newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.Then the tooth surface was rinsed with water and dried. Thereafter,Fuji Triage® was applied to the pits and fissures on the tooth surface using a brush. Thereafter, the varnish was applied and cured according to the manufacturer's instructions.
Study: NCT04696276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: special approaches in three phases preoperatively, intraoperatively and postoperatively, by an interdisciplinary team comprising of the surgeon, the anesthesiologist and the nurse. The combination of these techniques reduces the reaction to postoperative stress, relieves acute postoperative pain, restores the patient immediately to their original feeding and mobilization habits, thus reducing the time required for their complete recovery.
Study: NCT04707677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium and ceramic dental Implants
Description: Two types of implant placement and follow-up to compare the esthetic, clinical and radiographic parameters between them.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium and ceramic dental Implants
Description: Two types of implant placement and follow-up to compare the esthetic, clinical and radiographic parameters between them.
Study: NCT04854720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuji Triage® CAPSULE
Description: Fuji Triage® is a new generation glass ionomer containing with low viscosity, high fluoride content and light curing materials. Since the product is tolerant of moisture and saliva, it is used for fissure sealant of newly erupted teeth.~Control newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.Then the tooth surface was rinsed with water and dried. Thereafter,Fuji Triage® was applied to the pits and fissures on the tooth surface using a brush. Thereafter, the varnish was applied and cured according to the manufacturer's instructions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuji Triage® CAPSULE
Description: Fuji Triage® is a new generation glass ionomer containing with low viscosity, high fluoride content and light curing materials. Since the product is tolerant of moisture and saliva, it is used for fissure sealant of newly erupted teeth.~Control newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.Then the tooth surface was rinsed with water and dried. Thereafter,Fuji Triage® was applied to the pits and fissures on the tooth surface using a brush. Thereafter, the varnish was applied and cured according to the manufacturer's instructions.
Study: NCT02214927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 drinking solution
Study: NCT05477979

Intervention type: OTHER
Intervention: Exposure: psychological stress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.

Intervention type: OTHER
Intervention: Exposure: psychological stress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.

Intervention type: OTHER
Intervention: Exposure: psychological stress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.

Intervention type: OTHER
Intervention: Exposure: psychological stress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
Study: NCT04437069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Participants will view a Decision Aid (delivered as an app) that provides them with information regarding congenital heart disease, as described in the literature. The DA is tailored to the specific diagnosis of the fetus/neonate, so that participants are only viewing information about their baby's specific CHD diagnosis (and not other types of CHD). This is shown using videos and diagrams to clearly explain the defect, what their treatment options are (surgical intervention, comfort care, or termination), and personal stories from other parents who have dealt with the same diagnosis before (including both positive and negative outcomes). The DA was developed according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Participants will view a Decision Aid (delivered as an app) that provides them with information regarding congenital heart disease, as described in the literature. The DA is tailored to the specific diagnosis of the fetus/neonate, so that participants are only viewing information about their baby's specific CHD diagnosis (and not other types of CHD). This is shown using videos and diagrams to clearly explain the defect, what their treatment options are (surgical intervention, comfort care, or termination), and personal stories from other parents who have dealt with the same diagnosis before (including both positive and negative outcomes). The DA was developed according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Values Clarification Exercise
Description: The Values Clarification Exercise is a process that aids patients in clarifying their values and goals to improve alignment of their preferences with their chosen treatment. It was developed according to the International Patient Decision Aid Standards. It includes ten values that were chosen based on feedback from the parent investigators and clinicians. The ten values are: 1) discomfort to the child, 2) time in the hospital, 3) risk that the child will have impairments, 4) need to provide home medical care, 5) chronic medical care/decisions, 6) financial issues, 7) life in adulthood, 8) impact on the family, 9) beliefs about doing everything medically possible, \& 10) life expectancy. Each value has a sliding scale where the user can compare 2 treatment options at a time. They are asked which described situation feels better for them and their family.
Study: NCT00838318

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Audiotaped Phone Interview/Survey, 30 - 45 minutes.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Audiotaped Phone Interview/Survey, 30 - 45 minutes.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Audiotaped Phone Interview/Survey, 30 - 45 minutes.
Study: NCT04648059

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling will be performed to allow analyses of epigenetic markers

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling will be performed to allow analyses of epigenetic markers
Study: NCT00508586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC299
Description: PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
Study: NCT01559025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Vildagliptin ( Galvus 50mg twice day) during one year
Study: NCT04820699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post isometric relaxation and muligan bent leg raise
Description: 6 week intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muligan bent leg raise
Description: muligan bent leg raise
Study: NCT00765518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: CRCs will be administered via direct injection into the heart muscle.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Because the eligible patients had no other cardiac surgery or percutaneous cardiac interventions that were likely to produce clinical improvement, SOC was limited to pharmacologic therapy, heart transplant, or ventricular assist device therapy.
Study: NCT02384746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
Study: NCT03921125

Intervention type: DEVICE
Intervention: Massimo for Pleth variability index
Description: To assess fluid response
Study: NCT04450082

Intervention type: PROCEDURE
Intervention: One anastomosis gastric bypass
Description: The linear stapler divides the stomach horizontally at the junction of the corpus and antrum at the level of crow's foot. In cases where the pre-operative study has shown the presence of the gastric fundus, if possible the fundus was dissected and a long, narrow gastric pouch was designed starting from beyond the crow's foot to just lateral the angle of His over a 42-Fr orogastric tube. Gastrojejunostomy was then performed between 200-220 cm distally to the ligament of Treitz using a 45-mm.
Study: NCT02251418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Study: NCT02693028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic lozenges
Description: The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenges
Description: The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic capsules
Description: The women participating in the study will take two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The women participating in the study will take two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic chewing gum
Description: The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Study: NCT05088174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule
Description: Drug:~Hetrombopag Olamine Tablet Ciclosporin Soft Capsule
Study: NCT00708552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-742457
Description: investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-742457
Description: investigational drug
Study: NCT04171102

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProFlor Hernia implant
Description: Inguinal hernia repair

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProFlor Hernia implant
Description: Inguinal hernia repair

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProFlor Hernia implant
Description: Inguinal hernia repair
Study: NCT01756950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 mg/kg CR8020
Description: administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 mg/kg CR8020
Description: administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 mg/kg CR8020
Description: administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg CR8020
Description: administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg CR8020
Description: administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 mg/kg CR8020
Description: administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered as a single 2-hour intravenous infusion
Study: NCT00708552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator